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VaccineINTRODUCTION
Despite significant advances in surgical techniques,
irradiation, and chemotherapy, central nervous system
(CNS) tumors are the second-leading cancer-related
cause of death in children [1]. Many of those fortunate
enough to survive their CNS tumors are left with life-
long deficits resulting from their treatments [2].
Thus, investigators are exploring new therapeutic ap-
proachesmore specifically targeted against the tumors,
resulting in better tumor kills with fewer long-term
side effects.
Immunotherapeutic approaches to treating CNS
tumors are currently of significant interest. These
approaches include passive immunotherapy through
the use of monoclonal antibodies (mAbs), adoptive
immunotherapy through the use of ex vivo expanded
tumor-specific T cells, and active immunotherapy
through the use of tumor lysate and peptide vaccines.PASSIVE IMMUNOTHERAPY (SHARON L.
GARDNER)
mAbs offer the advantage of attaching specifically to
tumor antigens causing cell death through antibody-
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[3]. In addition, mAbs can be used as vehicles to deliver
cytotoxic agents, such as irradiation and toxins directly
to the tumor cells.
Several mAbs, including rituximab (anti-CD20),
myelotarg (anti-CD33), and alemtuzumab (anti-
CD52), are used to treat leukemia and lymphoma [4].
mAbs also have produced responses in children with
metastatic neuroblastoma [5]. Although several trials
incorporating monoclonal antibodies are underway,
the role of these antibodies in treating pediatric CNS
tumors has not yet been definitively established.
Similar to other malignancies, CNS tumors offer
the challenge of identifying unique antigens for the an-
tibodies to target. Epidermal growth factor receptor
(EGFR) is a target that has been studied in both adult
and pediatric brain tumors. Studies have shown that
EGFR is overexpressed, amplified, or mutated in a sig-
nificant proportion of high-grade gliomas [6].Nimotu-
zumab, a humanized IgG1 antibody directed against
the extracellular ligand-binding domain of EGFR, is
one of several mAbs developed to target abnormal
signaling through EGFR. In a phase II study of nimo-
tuzumab in children and adolescents with refractory
high-grade gliomas, 12 of 34 patients had a partial
response or stable disease after 2months of therapy, in-
cluding 9 of 14 patients with diffuse intrinsic brainstem
gliomas [7].
mAbs have been used to deliver toxins and irradia-
tion directly to tumor cells. The use of toxin or irradi-
ation-conjugated mAbs precludes the need for
complement-mediated lysis, which can be difficult in
the CNS. Radiation-conjugated mAbs can be used
for diagnostic purposes as well as to deliver radiation
therapy.
Tenascin is one of the most widely used targets for
radioimmunotherapy. Tenacin-C, an extracellular ma-
trix glycoprotein, is expressed several-fold greater in
high-grade gliomas than in normal brain tissue [8]. In
a phase II trial of I131-labeled anti-tenacin antibody,S75
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grade glioma exceeded that exceeded in historical con-
trols treated with irradiation and chemotherapy [9].
Radiolabeled mAbs also have been used to treat pa-
tients with refractory primitive neuroectodermal tu-
mors (PNETs) with leptomeningeal dissemination. in
19 patients with refractory PNETwithmeasurable dis-
ease, mAbs labeled with I131 were chosen from a panel
of antibodies based on binding with each individual tu-
mor and absence of binding on normal CNS tissue.
The overall response rate was 64% (complete response
[CR], 37%; partial response [PR], 16%; stable disease
[SD], 11%) [10].
Targeted therapy also has been explored through
the use of toxins conjugated to ligands, such as trans-
forming growth factor (TGF)-a and transferrin, which
bind to receptors overexpressed on brain tumors. Pseu-
domonas exotoxin conjugated withTGF-a enables de-
livery of the exotoxin to glioma cells throughbinding to
EGFRs [11]. A diphtheria-transferrin conjugate has
been used to treat glioma by exploiting the enhanced
expression of transferrin receptors on glioma cells [12].
Along with directly targeting tumor cells, many in-
vestigators are examining the environment surround-
ing the tumors as well. More than 30 years ago,
Judah Folkman hypothesized that tumors could be
contained with drugs that prevent the development
of new blood vessels to feed the tumors [13]. Bevacizu-
mab is a monoclonal antibody that targets vascular en-
dothelial growth factor [14]. Investigators at Duke
combined bevacizumab with irinotecan in adults with
recurrent malignant glioma, and found an objective re-
sponse rate of 57% and a 6-month progression-free
survival (PFS) of 46% [15]. Although some small pre-
liminary studies in children with refractory high-grade
gliomas have not shown a benefit with bevacizumab,
there is a suggestion that it may be efficacious in chil-
dren with low-grade gliomas. In a small pilot study of
10 children with low-grade gliomas with refractory
disease after exhausting all conventional treatments,
7 of 9 evaluable patients had a minor, partial, or com-
plete radiographic response, as well as clinical im-
provement, following 2 courses of bevacizumab and
irinotecan [16]. At the time of the report, 6 children re-
mained on therapy for between 3 and 22 months, and 8
children were progression-free survivors. The therapy
was well tolerated; only 2 patients suffered a dose-
limiting toxicity, with transient leukoencephalopathy
in one and grade 3 proteinuria in the other.ADOPTIVE CELLULAR THERAPIES FOR
BRAIN TUMORS (NABIL AHMED)
Immunotherapy with T cells has been most suc-
cessful in hematopoietic stem cell transplantation
(HSCT) recipients, in whom the T cell source is nor-mal marrow donors. Adoptive immunotherapy with
donor lymphocyte infusion (DLI) has been used to
effectively augment the graft-versus-leukemia (GVL)
response and to treat Epstein-Barr virus (EBV)-
associated lymphoproliferative disease after HSCT;
however, DLI is associated with a high risk of
graft-versus-host disease (GVHD) and is not always
effective [17-20]. Selectively activated and/or expanded
cytomegalovirus (CMV)- or EBV-specific cytotoxic T
lymphocytes (CTLs) have been successful in restoring
immune response and preventing diseases associated
with these viruses without causing GVHD [21].Factors Limiting the Application of Antigen-
Specific T Cell Therapy
The broader use of antigen-specific CTLs for
tumor therapy is currently limited by several factors,
including (1) the reliable generation of tumor-specific
T cells; (2) decreased major histocompatibility (MHC)
class I expression on tumor cells or defects in the anti-
gen-processing machinery; (3) the presence of inhibi-
tory T cells, such as T helper type 2 (Th2) cells and/
or T regulatory cells (Tregs), at the tumor site; and
(4) limited in vivo expansion of adoptively transferred
T cells. One strategy for overcoming many of these
limitations is the genetic modification of T cells to ex-
press chimeric antigen receptors (CARs). CARs are
synthetic molecules consisting of an extracellular re-
ceptor domain (ectodomain) that contains the heavy-
chain and light-chain variable regions of an mAb
joined to a transmembrane and a cytoplasmic-signal-
ing domain (endodomain) derived from the CD3-x
chain and costimulatory molecules such as CD28,
OX40, and 4-1BB (Figure 1) [22,23]. CARs provide
T cell activation in a non-MHC-restricted manner
and thereby circumvent some of the major mecha-
nisms by which tumors avoid MHC-restricted T cell
recognition, such as downregulation of HLA class I
molecules and defects in antigen processing. More-
over, expressing CARs with multiple signaling do-
mains in T cells renders them resistant to the
inhibitory effects of regulatory Tregs [24]. Finally,
CAR-expressing T cells can be readily prepared in
large quantities ex vivo for clinical applications.
Indeed, our preliminary results indicate that T cells
expressing CARs specific for the human epidermal
growth factor receptor 2 (HER2) could overcome
several of the current limitations of malignant
glioma-specific T cell therapies.
Human epidermal growth factor receptor 2 (Her2)
has been used as a T cell therapy target in malignant
gliomas. The ideal target for biological therapies is
one that distinguishes tumor cells from normal sur-
rounding tissue, thereby avoiding unwanted bystander
effects. In addition, the therapeutic target should be
essential to the malignant phenotype of cancer cells,
Figure 1. CARs consist of an extracellular antigen-recognition domain
(ectodomain), a transmembrane domain, and an intracellular signaling
domain (endodomain). A CAR with a CD3-x signaling domain is shown.
Additional signaling domains derived from costimulatory molecules can
be introduced into the endodomain to enhance CAR-mediated T cell
activation.
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satisfies these criteria in malignant gliomas. HER2
protein is present in up to 80% of glioblastoma multi-
formes (GBMs) [25,26], but not in the normal postna-
tal brain [27]. HER2 signaling deregulates cell
proliferation, inhibits apoptosis, and increases the
metastatic potential of cancer cells [28-30]. Moreover,
HER2 expression increases with the degree of anapla-
sia in glial tumors [26,28,29,31,32]. The median sur-
vival for GBM patients with HER2-overexpressing
tumors was 4 months, compared with approximately
14 months for patients whose tumors lacked overex-
pression [26]. This observation, along with the fact
that HER2 is not expressed by normal postnatal hu-
man brain cells [33], makes HER2 an attractive target
for biological therapies for malignant glioma.
HER2 is a validated target for breast cancer immu-
notherapy [28,34-36]; however, the HER2 expression
is low on GBM, making HER2 mAbs like trastuzumab
less effective [37-39]. Our preliminary results suggests
that genetic modification of T cells with HER2-
specific CARs effectively overcomes this limitation,
because the overall avidity of receptors arrayed on
a T cell is greater than that of a bivalent antibody,
and engagement of a limited number of T cell receptor
molecules is sufficient to trigger a cytotoxic effector
response [37].CMVand GlioblastomaMultiforme: An Evolving
Association
Cytomegalovirus (CMV) is a ubiquitous beta-her-
pes virus that produces a minor mononucleosis-like
syndrome in the immunocompetent host. Several re-
cent reports have identified immunoreactivity for the
CMV proteins pp65 (CMVpp65) and IE1-72 by
immunohistochemistry (IHC) in 80% to 100% of
GBM samples studied, as well as CMV RNA by insitu hybridization (ISH) in all IHC-positive samples
[40,41]. In addition, CMV DNA as well as viral parti-
cles were detected in pp65 and IE1-72 immunoreac-
tive cells. It is likely that CMV promotes the
malignant phenotype of GBM cells by enhancing cell
invasiveness and activating telomerase [42]. Although
the presence of CMV antigens in GBMs is controver-
sial, recent results of phase II clinical studies with den-
dritic cell (DC) vaccines unequivocally support their
presence. Patients with newly diagnosed GBM vacci-
nated with CMVpp65-RNA-transfected DCs have
a longer PFS than nonvaccinated controls, and 1
patient enrolled on the DCVax study (DC pulsed
with autologous tumor lysate) developed a strong
CMV-specific T cell response after vaccination [43].ENHANCING THE IN VIVO EXPANSION AND
PERSISTENCE OF ADOPTIVELY
TRANSFERRED CAR T CELLS
Full T cell activation requires that receptor en-
gagement be accompanied by a sequence of costimula-
tory stimuli. Such a sequence is usually lacking when
a synthetic CAR is engaged. To overcome this limita-
tion, investigators have grafted CARs into CTLs with
defined antigen specificity, including CTLs specific
for EBV [44,45]. These cells not only provide antitu-
mor activity through their CAR component, but also
receive appropriate costimulation following native T
cell receptor engagement by EBV-latent antigens pre-
sented by APCs. For GBM-targeted T cell therapies,
we explored using CTLs specific for a different latent
herpes virus, CMV. This may be a superior proposi-
tion, because CMV antigens are present not only in
latently infected leukocytes, but also in most GBMs.MOLECULARLY TARGETEDVACCINE
STRATEGIES FOR ADULTAND PEDIATRIC
PATIENTS WITH GLIOMA (HIDEHO OKADA)
Introduction
Brain tumors, like other malignancies, are able to
overcome host immune defenses through various
mechanisms that have become increasingly well char-
acterized over the past decade [46]. Immunologic tol-
erance of brain tumors may result in part from the
absence of conventional draining lymphatics, which
limits primary immune responses initiated within the
CNS. Furthermore, the normal and neoplastic brain
tissues elaborate a variety of immunosuppressive fac-
tors, including TGF-b2, Fas ligand (CD95L), and
programmed death ligand-1 (PDL-1). This ‘‘immuno-
logically privileged’’ status of the brain is not absolute,
however. Systemic activation of T cell responses
against brain-specific antigens induces immune
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perimental allergic encephalomyelitis [47] and para-
neoplastic cerebellar degeneration [48].
For more than a decade, we have been dedicated to
developingnovel immunization approaches for patients
withCNS tumors, such as gliomas. Early-phase clinical
trials by us [49,50] and others of more than 100 patients
with malignant glioma have demonstrated the safety
and preliminary therapeutic benefits of peripheral vac-
cinations using autologous glioma tissue-derived bulk
antigens [46]. To develop tumor-specific (ie, safer)
and effective glioma vaccines, we have focused our re-
search efforts on identifying and characterizing human
glioma-associated antigen (GAA)-derived CTL epi-
topes, such as those in the interleukin-13 receptor
(IL-13R)a2 [51] and EphA2 [52].
But, the rejection of tumors by GAA-specific vac-
cines is the final outcome of a series of events initiated
by an immune or inflammatory response at the site of
vaccination. Vaccine-induced GAA-specific T cells are
required to traffic into the tumor sites in sufficient
numbers, retain their functionality, and exert their an-
titumor activities. Given the unique immunologic en-
vironment of the CNS and CNS tumors, we propose
that the systemic induction of GAA-specific responses
by peripheral vaccines must be followed by therapeutic
interventions that enhance the attraction and promote
the functionality of vaccine-induced effector cells
within the CNS tumor site for optimal efficacy.
Type-1 CTL Response for Anti-CNS Tumor
Immunotherapy
Our previous preclinical studies have indicated that
efficientCNStumorhoming is a characteristic ofCTLs
with type 1 phenotype (Tc1) as opposed to those with
type 2 phenotype (Tc2), and appears to be mediated
by a type 1 chemokine, CXCL10/IP-10 [53]. Further
characterization of the expression of a panel of homing
receptors on Tc1 and Tc2 cells showed that only very
late antigen (VLA)-4 (a heterodimer of CD49d and
CD29) was expressed at significantly higher levels on
Tc1 cells than on Tc2 cells [54]. VLA-4 expression on
T cells was downregulated in an IL-4 dose-dependent
manner but not by other type 2 cytokines (eg, IL-10,
IL-13), suggesting that IL-4 uniquely downregulates
VLA-4 expression on these T cells . The efficient traf-
ficking of Tc1 cells into intracranial tumors in vivo
was efficiently blocked by administration of mAbs
against CD49d or VCAM-1 or small interfering
RNA-mediated silencing of CD49d on Tc1 cells, sup-
porting the critical role of VLA-4 in the effective intra-
cranial tumor homing of antigen-specific Tc1 cells.
These data also suggest that effective vaccine and/or
ex vivo T cell activation regimens may be developed
by promoting the generation of VLA-41 antitumor
Tc1 cells.Poly-ICLC as an Attractive Adjuvant to
Promote Type-1 Antiglioma Immunity
A clinically relevant type 1 polarizing regimen may
be achieved by poly-ICLC, a natural type 1 interferon
(IFN) inducer. Poly-ICLCis a synthetic complexof car-
boxymethylcellulose, polyinosinic-polycytidylic acid,
and poly-L-lysine double-stranded RNA that has been
extensively investigated in clinical trials and found to
stimulate the release of type 1 cytokines and chemokines
by dendritic cells, thereby increasing the tumoricidal
activities of various immune effector cells via stimula-
tion of TLR3 and MDA5 [55] (also see the National
Cancer Institute website: http://www.cancer.gov/Tem-
plates/drugdictionary.aspx?CdrID539559).
TLR3 is involved in the recognition of viral com-
ponents, such as viral double-stranded (ds)RNA [56].
The CNS requires rapid, innate immune responses
by resident brain cells to effectively fight infectious
agents in theCNS.Recent studies have analyzed the ex-
pression and function ofTLRs inmicroglia [57] and as-
trocytes [58,59]. In human astrocytes, TLR3 had the
highest relative expression level among TLRs 1-10,
whereas mouse and human microglia expressed
mRNA for all of the recently identified TLRs [57]. It
also has beennoted that poly-IC is capable of efficiently
inducing the production of proinflammatory cyto-
kines, such as IFN-b, IL-6, and TNF-a, and chemo-
kines, such as CCL2/MCP-1, CCL5/RANTES,
CCL20/MIP-3a, andCXCL10/IP-10, fromastrocytes
and microglia [58,59]. These data demonstrate that
stimulation of TLR3 pathway may be key for expand-
ing and directing systemic immunity into the CNS.
Poly-ICLC has been extensively evaluated in
patients with gliomas. In the first pilot study [60], 38
patients with malignant gliomas received i.m. injec-
tions of poly-ICLC. Minimal toxicity was associated
with the treatment. Antitumor response was associated
with activation of 2’,5’-oligoadenylate synthetase
(OAS), type 1 IFN-induced proteins with antiviral
properties, suggesting a biological activity of this reg-
imen in humans. Recently, the North American Brain
Tumor Consortium (NABTC) sponsored 2 phase II
trials of poly-ICLC. In one trial, 30 adults with newly
diagnosed GBM received poly-ICLC in combination
with, and after, radiation therapy (RT) [61]. The study
suggested a survival advantage compared with histori-
cal studies using RT without chemotherapy, but no
survival advantage compared with RT with adjuvant
nitrosourea or non-temozolomide chemotherapy.
However, the other phase II study failed to show clin-
ical efficacy of poly-ICLC as monotherapy in 45 pa-
tients with recurrent GBM or anaplastic glioma (AG)
compared with an historical database [62]. These 2
studies, based on the association of antitumor response
with activation of 2’,5’-OAS, suggest that better clini-
cal outcomes may be achieved by using poly-ICLC in
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vaccines.
Usingmouse brain tumormodels, we have demon-
strated that i.m. administration of poly-ICLC en-
hances the effect of peripheral vaccinations with
GAA-derived CTL epitopes [63]. Specifically, this
combination strategy can promote induction of
GAA-specific CTLs and survival of glioma-bearing
mice without CNS autoimmunity, and CNS-tumor
infiltration of GAA-specific CTLs expressing VLA-4,
a critical homing receptor to CNS tumors [54].
Early-Phase Evaluation of Vaccinations Using
Type-1 Polarizing DCs Loaded with GAA-
DerivedCTLEpitopes andPoly-ICLC In Patients
with Recurrent Malignant Glioma
Based on these inventions by our laboratory, we re-
cently implemented a novel phase I/II vaccine trial de-
signed to maximize the induction of type 1 anti-GAA
CTL responses in patients with recurrent malignant
glioma (UPCI 05-115). Patients with recurrent GBM
or anaplastic glioma are vaccinated with 1-3  107
type 1 polarizing DCs (aDC1) [64] loaded with syn-
thetic peptide encoding GAA-derived HLA-A2-bind-
ing CTL epitopes (EphA2 883-891, IL-13Ra2 345: 1A9V,
YKL-40 201-210, and GP100 209-217:M2) once every 2
weeks (minimum 4 vaccinations) by ultrasound-guided
injection into lymph nodes. These patients also receive
i.m. injections of poly-ICLC twice a week (20 mg/kg).
This study was designed to evaluate the safety (primary
objective) and induction of anti-GAA immunity and
clinical response (secondary objectives) of the regimen.
aDC1s have been shown to be more potent than con-
ventional DCs in induction of antigen-specific CTL
responses [64].
To date, we have enrolled a total 21 patients and
completed 4 scheduled vaccinations in 18 participants.
No Common Terminology Criteria for Adverse Events
(CTCAE) grade 3 or higher adverse events were
reported. None of the patients enrolled in this trial
have demonstrated any clinical indices, radiologic signs,
or laboratory data suggesting autoimmunity. Immune
responses have been evaluated in participants who
received at least 4 vaccinations, using ELISPOT and/
or tetramer assays. These interim data demonstrate for
thefirst time inductionof specific reactivity againstnovel
IL-13Ra2- and EphA2-derived epitopes in vaccine
recipients. Interestingly, Fisher’s exact test indicated an
association between positive tetramer response and
6-month PFA (P 5 .040 [1-sided] and .048 [2-sided]),
suggesting a possible correlation between tetramer-de-
tected immune responses and clinical response.
Conclusion
Several different immunotherapy strategies for
treatingCNS tumors are currently under investigation.CNS tumors pose multiple challenges that must be
overcome for these therapies to be effective. Obstacles
include the inability to obtain tumor tissue from many
patients, the need for steroids to decrease swelling, and
the inability of many large molecules to cross the
blood-brain barrier. Several different approaches in-
cluding those presented in this paper are being explored
in order to overcome these obstacles. More work is
needed to better understand how to increase the effi-
cacy of these strategies and how best to incorporate
them into the overall treatment plan for these patients.ACKNOWLEDGMENTS
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